A Novel Precision Approach to Overcome the “Addiction Pandemic” by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration
暂无分享,去创建一个
K. Blum | P. Thanos | R. Badgaiyan | D. Baron | E. Modestino | T. McLaughlin | M. Gold | I. Elman | D. Bagchi | A. Bowirrat | Rehan Jalali | Shan Kazmi | B. Downs | Richard Green | Edward J. Modestino
[1] J. H. Chen,et al. Synaptamine (SG8839),TM An Amino-Acid Enkephalinase Inhibition Nutraceutical Improves Recovery of Alcoholics, A Subtype of Reward Deficiency Syndrome (RDS) , 2007 .
[2] M. Oscar-Berman,et al. Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[3] O. Andreassen,et al. A global overview of pleiotropy and genetic architecture in complex traits , 2019, Nature Genetics.
[4] N. Braidy,et al. Sobriety and Satiety: Is NAD+ the Answer? , 2020, Antioxidants.
[5] P. Molinoff,et al. Differential coupling of rat D2 dopamine receptor isoforms expressed in Spodoptera frugiperda insect cells. , 1996, The Journal of pharmacology and experimental therapeutics.
[6] Peter A. Groblewski,et al. Excessive cocaine use results from decreased phasic dopamine signaling in the striatum , 2014, Nature Neuroscience.
[7] M. Gold. The Role of Alcohol, Drugs, and Deaths of Despair in the U.S.'s Falling Life Expectancy. , 2020, Missouri medicine.
[8] R. Spanagel,et al. The Inhibition of RasGRF2, But Not RasGRF1, Alters Cocaine Reward in Mice , 2019, The Journal of Neuroscience.
[9] A. Malhotra,et al. Dopamine D2 receptor density and personal detachment in healthy subjects. , 1998, The American journal of psychiatry.
[10] Z. Ruan,et al. Primary studies on heroin abuse and injury induced by oxidation and lipoperoxidation. , 2001, Chinese medical journal.
[11] K. Blum,et al. Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems. , 2018, Frontiers in bioscience.
[12] L. Becerra,et al. Reward and aversion processing in patients with post-traumatic stress disorder: functional neuroimaging with visual and thermal stimuli , 2018, Translational Psychiatry.
[13] K. Blum,et al. Reward Deficiency Syndrome: Attentional/Arousal Subtypes, Limitations of Current Diagnostic Nosology, and Future Research , 2015, Journal of reward deficiency syndrome.
[14] Blum Kenneth,et al. Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated) , 2018, CPQ neurology and psychology.
[15] Nils B. Kroemer,et al. Fuel not fun: Reinterpreting attenuated brain responses to reward in obesity , 2016, Physiology & Behavior.
[16] N. Fernàndez-Castillo,et al. Genome-wide association meta-analysis of cocaine dependence: shared genetics with comorbid conditions , 2018 .
[17] K. Blum,et al. Neurogenetics of acute and chronic opiate/opioid abstinence: treating symptoms and the cause. , 2017, Frontiers in bioscience.
[18] X. Chu,et al. Nicotinamide phosphoribosyltransferase contributes to cocaine addiction through sirtuin 1. , 2019, International journal of physiology, pathophysiology and pharmacology.
[19] H. Frieling,et al. Alterations in DNA-methylation of the dopamine-receptor 2 gene are associated with abstinence and health care utilization in individuals with a lifetime history of pathologic gambling , 2015, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[20] C. Adler,et al. Effects of Acute Metabolic Stress on Striatal Dopamine Release in Healthy Volunteers , 2000, Neuropsychopharmacology.
[21] N. Volkow,et al. Pain and suicidality: Insights from reward and addiction neuroscience , 2013, Progress in Neurobiology.
[22] Benjamin P Linas,et al. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. , 2018, Journal of substance abuse treatment.
[23] William B. Downs,et al. Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms. , 2012, Journal of addiction research & therapy.
[24] M. Rietschel,et al. Genome-wide association study of pathological gambling , 2016, European Psychiatry.
[25] K. Blum,et al. Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z , 2017, PloS one.
[26] M. Gold,et al. Treatment resistant opioid use disorder (TROUD): Definition, rationale, and recommendations , 2020, Journal of the Neurological Sciences.
[27] P. Molinoff,et al. Agonists and antagonists differentially regulate the high affinity state of the D2L receptor in human embryonic kidney 293 cells. , 1995, Molecular pharmacology.
[28] E. Bakhshi,et al. Opioid Use Disorder Induces Oxidative Stress and Inflammation: The Attenuating Effect of Methadone Maintenance Treatment , 2018, Iranian journal of psychiatry.
[29] K. Blum,et al. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS) , 2020, Journal of the Neurological Sciences.
[30] D. Borsook,et al. The failing cascade: Comorbid post traumatic stress- and opioid use disorders , 2019, Neuroscience & Biobehavioral Reviews.
[31] D. Borsook,et al. Psychological processing in chronic pain: A neural systems approach , 2014, Neuroscience & Biobehavioral Reviews.
[32] K. Blum,et al. The Food and Drug Addiction Epidemic: Targeting Dopamine Homeostasis. , 2017, Current pharmaceutical design.
[33] C. McClung,et al. NAD+ cellular redox and SIRT1 regulate the diurnal rhythms of tyrosine hydroxylase and conditioned cocaine reward , 2018, Molecular Psychiatry.
[34] William B. Downs,et al. Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency , 2020, Journal of addiction science.
[35] M. Ernst,et al. Neuroimaging of the dopamine/reward system in adolescent drug use , 2015, CNS Spectrums.
[36] P. Magistretti,et al. Hypocretin/orexin deficiency decreases cocaine abuse liability , 2018, Neuropharmacology.
[37] K. Blum,et al. Conceptualizing Addiction From an Osteopathic Perspective: Dopamine Homeostasis , 2018, The Journal of the American Osteopathic Association.
[38] B. Seifi,et al. Impact of opioids on oxidative status and related signaling pathways: An integrated view. , 2017, Journal of opioid management.
[39] A. Bonci,et al. Rehabilitating the addicted brain with transcranial magnetic stimulation , 2017, Nature Reviews Neuroscience.
[40] Thomas J. H. Chen,et al. Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence. , 2018, Frontiers in bioscience.
[41] D. Kouretas,et al. Buprenorphine and Methadone as Opioid Maintenance Treatments for Heroin-Addicted Patients Induce Oxidative Stress in Blood , 2019, Oxidative medicine and cellular longevity.
[42] Ramzi W. Nahhas,et al. Post-traumatic stress symptoms in pathological gambling: Potential evidence of anti-reward processes , 2017, Journal of behavioral addictions.
[43] John G. Cull,et al. REWARD DEFICIENCY SYNDROME , 1996 .
[44] D. Wedekind,et al. Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder , 2015, Human psychopharmacology.
[45] Natalie J. Loxton,et al. ‘Food addiction’ and its association with a dopaminergic multilocus genetic profile , 2013, Physiology & Behavior.
[46] K. Reissner,et al. The effects of nicotinamide on reinstatement to cocaine seeking in male and female Sprague Dawley rats , 2019, Psychopharmacology.
[47] K. Blum,et al. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome? , 2020, Journal of the Neurological Sciences.
[48] Kosha Ruparel,et al. Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. , 2008, The American journal of psychiatry.
[49] K. Blum,et al. Allelic association of human dopamine D2 receptor gene in alcoholism. , 1990, JAMA.
[50] Thomas J. H. Chen,et al. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary , 2008, Theoretical Biology and Medical Modelling.
[51] J. Costas,et al. Relationships between substance abuse/dependence and psychiatric disorders based on polygenic scores , 2018, Genes, brain, and behavior.
[52] William B. Downs,et al. Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair. , 2019, Current pharmaceutical biotechnology.
[53] K. Blum,et al. The therapeutic potential of exercise for neuropsychiatric diseases: A review , 2020, Journal of the Neurological Sciences.
[54] K. Blum,et al. Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual , 2020, Journal of Systems and Integrative Neuroscience.
[55] C. Eccleston,et al. When pain gets stuck: the evolution of pain chronification and treatment resistance , 2018, Pain.
[56] K. Blum,et al. Buprenorphine Response as a Function of Neurogenetic Polymorphic Antecedents: Can Dopamine Genes Affect Clinical Outcomes in Reward Deficiency Syndrome (RDS)? , 2014, Journal of addiction research & therapy.
[57] K. Blum,et al. Administration of a putative pro-dopamine regulator, a neuronutrient, mitigates alcohol intake in alcohol-preferring rats , 2020, Behavioural Brain Research.
[58] J. Han,et al. Putative oxidative metabolites of 1-methyl-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline of potential relevance to the addictive and neurodegenerative consequences of ethanol abuse. , 1997, Alcohol.
[59] P. O'hollaren. Diphosphopyridine nucleotide in the prevention, diagnosis and treatment of drug addiction. A preliminary report. , 1961, Western journal of surgery, obstetrics, and gynecology.
[60] E. Nestler,et al. Regulation of G proteins by chronic morphine in the rat locus coeruleus , 1989, Brain Research.
[61] X. Cen,et al. 1H‐nuclear magnetic resonance‐based metabonomic analysis of brain in rhesus monkeys with morphine treatment and withdrawal intervention , 2012, Journal of neuroscience research.
[62] L. Tampier,et al. Effect of nicotinamide administration on ethanol consumption and on liver and brain acetaldehyde oxidation rate, by UChB rats , 1999, Addiction biology.
[63] K. Blum,et al. Our evolved unique pleasure circuit makes humans different from apes: Reconsideration of data derived from animal studies , 2018, Journal of systems and integrative neuroscience.
[64] S. Schwartz,et al. The Roles of Dopamine and Hypocretin in Reward: A Electroencephalographic Study , 2015, PloS one.
[65] P. Skolnick,et al. The Opioid Epidemic: Crisis and Solutions. , 2018, Annual review of pharmacology and toxicology.
[66] Tanzil Mahmud Arefin,et al. Increased Alcohol Seeking in Mice Lacking Gpr88 Involves Dysfunctional Mesocorticolimbic Networks , 2018, Biological Psychiatry.
[67] H. Famitafreshi,et al. Socialization Alleviates Burden of Oxidative-Stress in Hippocampus and Prefrontal Cortex in Morphine Addiction Period in Male Rats. , 2018, Current molecular pharmacology.
[68] K. Blum,et al. Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality , 2015, Clinical medical reviews and case reports.
[69] L. Becerra,et al. Yohimbine-Induced Amygdala Activation in Pathological Gamblers: A Pilot Study , 2012, PloS one.
[70] David E. Smith,et al. Neurogenetic and epigenetic correlates of adolescent predisposition to and risk for addictive behaviors as a function of prefrontal cortex dysregulation. , 2015, Journal of child and adolescent psychopharmacology.
[71] K. Blum,et al. Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors , 2018, Front. Psychiatry.
[72] K. Ikeda,et al. Opioid and nondopamine reward circuitry and state‐dependent mechanisms , 2019, Annals of the New York Academy of Sciences.
[73] K. Blum,et al. Co-occurrences of substance use and other potentially addictive behaviors: Epidemiological results from the Psychological and Genetic Factors of the Addictive Behaviors (PGA) Study , 2020, Journal of behavioral addictions.
[74] D. Hommer,et al. Imaging brain response to reward in addictive disorders , 2011, Annals of the New York Academy of Sciences.
[75] Carsten Marr,et al. Zebrafish reward mutants reveal novel transcripts mediating the behavioral effects of amphetamine , 2009, Genome Biology.
[76] K. Blum,et al. “Dopamine homeostasis” requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America’s drug epidemic , 2017, Journal of systems and integrative neuroscience.
[77] A. Griffa,et al. N-Acetyl-Cysteine Supplementation Improves Functional Connectivity Within the Cingulate Cortex in Early Psychosis: A Pilot Study , 2019, The international journal of neuropsychopharmacology.
[78] H. Byun,et al. Morphine Induces Redox-Based Changes in Global DNA Methylation and Retrotransposon Transcription by Inhibition of Excitatory Amino Acid Transporter Type 3–Mediated Cysteine Uptake , 2014, Molecular Pharmacology.
[79] K. Blum,et al. Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction , 2015, Journal of reward deficiency syndrome.
[80] Yarong Wang,et al. rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts , 2015, Postgraduate medicine.
[81] M. R. Iyer,et al. Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist , 2018, Proceedings of the National Academy of Sciences.
[82] K. Blum,et al. Death by Opioids: Are there non-addictive scientific solutions? , 2019, Journal of systems and integrative neuroscience.
[83] K. Blum,et al. "Liking" and "wanting" linked to Reward Deficiency Syndrome (RDS): hypothesizing differential responsivity in brain reward circuitry. , 2012, Current pharmaceutical design.
[84] R. Veit,et al. Dopamine Depletion Reduces Food-Related Reward Activity Independent of BMI , 2016, Neuropsychopharmacology.
[85] Yuan-Chuan Chen,et al. Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review , 2019, International journal of molecular sciences.
[86] A. Lawrence,et al. The acute anti‐craving effect of acamprosate in alcohol‐preferring rats is associated with modulation of the mesolimbic dopamine system , 2005, Addiction biology.
[87] K. Blum,et al. In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing. , 2020, Current psychopharmacology.
[88] D. Borsook,et al. Neuroscience and Biobehavioral Reviews Reward Deficiency and Anti-reward in Pain Chronification , 2022 .
[89] M. Gutowicz,et al. The influence of heroin abuse on glutathione-dependent enzymes in human brain. , 2011, Drug and alcohol dependence.
[90] Y. Yau,et al. Stress and eating behaviors. , 2013, Minerva endocrinologica.
[91] K. Blum,et al. Opioid Substitution Therapy: Achieving Harm Reduction While Searching for a Prophylactic Solution. , 2019, Current pharmaceutical biotechnology.
[92] K. Lynch,et al. Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence , 2015, Translational Psychiatry.
[93] David Borsook,et al. The cerebellum and addiction: insights gained from neuroimaging research , 2014, Addiction biology.
[94] John P. Rice,et al. Identification of common genetic risk variants for autism spectrum disorder , 2019, Nature Genetics.
[95] L. Becerra,et al. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. , 2010, Brain : a journal of neurology.
[96] E. Huang,et al. Dopaminergic Neurons and Brain Reward Pathways: From Neurogenesis to Circuit Assembly. , 2016, The American journal of pathology.
[97] D. Borsook,et al. Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone , 2020, Scientific Reports.
[98] W. van den Brink,et al. CLINICAL STUDY: Predicting the effect of naltrexone and acamprosate in alcohol‐dependent patients using genetic indicators , 2009, Addiction biology.
[99] K. Blum,et al. Low-Resolution Electromagnetic Tomography (LORETA) of changed Brain Function Provoked by Pro-Dopamine Regulator (KB220z) in one Adult ADHD case. , 2016, Open journal of clinical & medical case reports.
[100] J. Vink. Genetics of Addiction: Future Focus on Gene × Environment Interaction? , 2016, Journal of studies on alcohol and drugs.
[101] K. Blum,et al. Acute Intravenous Synaptamine Complex Variant KB220™ “Normalizes” Neurological Dysregulation in Patients during Protracted Abstinence from Alcohol and Opiates as Observed Using Quantitative Electroencephalographic and Genetic Analysis for Reward Polymorphisms: Part 1, Pilot Study with 2 Case Reports , 2010, Postgraduate medicine.
[102] Louise Kaplan. Medication-assisted treatment for opioid use disorder. , 2018, The Nurse practitioner.
[103] S. Kühn,et al. Disruption of Reward Processing in Addiction: An Image-Based Meta-analysis of Functional Magnetic Resonance Imaging Studies , 2017, JAMA psychiatry.
[104] Steven M. Southwick,et al. Polygenic Scores for Major Depressive Disorder and Risk of Alcohol Dependence , 2017, JAMA psychiatry.
[105] K. Blum,et al. Genetic Addiction Risk Score (GARS™) as a Predictor of Substance Use Disorder: Identifying Predisposition Not Diagnosis. , 2018, Current trends in medical diagnostic methods.
[106] K. Blum,et al. Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis. , 2018, Biomedical journal of scientific & technical research.
[107] T. Cronholm,et al. Mechanism and regulation of ethanol elimination in humans: intermolecular hydrogen transfer and oxidoreduction in vivo. , 1988, Alcoholism, clinical and experimental research.
[108] Hong Lin,et al. Heroin-administered mice involved in oxidative stress and exogenous antioxidant-alleviated withdrawal syndrome. , 2006, Basic & clinical pharmacology & toxicology.
[109] Dai Zhang,et al. GABRA2 rs279858-linked variants are associated with disrupted structural connectome of reward circuits in heroin abusers , 2018, Translational Psychiatry.
[110] P. O’Reilly,et al. Cannabis use, depression and self-harm: phenotypic and genetic relationships , 2019, bioRxiv.